NASH 분석 서비스 | NASH Panel Assay Service | 고마바이오텍

• 간지방증 (liver steatosis) 유발과 관련된 6가지 타겟군에 속하는 13가지 target에 대한 스크리닝을 진행합니다.
  

Demonstrated data for the Liver Steatosis Panel. A. Two reported ACC1 inhibitors were validated by an enzymatic ACC1 inhibition assay. Firsocostat is a potent ACC1 inhibitor in Phase I trials for NASH. B. and D. Thyroid hormone mimetics and incretin analogues were examined by radioligand-based THRβ and GLP1R binding assays, respectively. C. Known AMPK activator, A769662, and endogenous agonist, AMP, were characterized via a biochemical AMPK activation assay. E. Two potential candidates of IBAT transporter inhibition were validated by a cell-based IBAT uptake assay. Odevixibat is a candidate against NASH in Phase II trials while Linerixibat is Phase II trials for T2DM.

2. Hepatitis Panel (#PP271)   

• Hepatitis 발생과 관련된 6가지 타겟군에 속하는 11가지 target에 대한 스크리닝을 진행합니다.   

Demonstrated data for the Hepatitis Panel. A. and B. Binding affinity of known CCR2 and CCR5 agonists were validated by radioligand-based binding assays. C. Reported VAP-1 inhibitors were examined by an enzymatic VAP-1 inhibition assay. PXS4728A is a Phase II candidate for NASH. 

3. Liver Fibrosis Panel (#PP272)   

• Liver fibrosis와 관련된 2가지 target에 대한 스크리닝을 진행합니다.  

Demonstrated data for the Liver Fibrosis Panel. A. ECM remodeling enzyme, LOXL2, was measured by the IC50 of two inhibitors by an enzymatic LOXL2 inhibition assay. PAT-1251 is in Phase I trials for lung fibrosis. B. Human HSC LX-2 cells were activated by 0.3 nM TGFβ for 48-hr. Fibrogenesis was monitored by evaluating the fibrogenetic marker collagen, type 1, α1 (COL1A1) expression level and analyzed by high-content imaging (Blue: Nuclei; Red: COL1A1). TGFβ successfully induced liver fibrosis with a high level of COL1A1 expression (Image, middle). Induced COL1A1 expression was dose-dependently inhibited by two TGFβ inhibitors, SB525334 and SB-431542, respectively.